← ACADIA PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $17.3m |
$124.9m
+620.68%
|
$223.8m
+79.19%
|
$339.1m
+51.50%
|
$441.8m
+30.28%
|
$484.1m
+9.60%
|
$517.2m
+6.83%
|
$726.4m
+40.45%
|
$957.8m
+31.85%
|
$1.1b
+11.87%
|
$1.1b
+6.27%
|
|
| Cost of Revenue | $3.1m |
$9.1m
+195.19%
|
$12.4m
+36.36%
|
$11.3m
-8.35%
|
$10.2m
-9.99%
|
$10.8m
+6.19%
|
$10.2m
-6.24%
|
$41.6m
+309.58%
|
$81.8m
+96.55%
|
$89.0m
+8.75%
|
$101.0m
+13.46%
|
|
| Gross Profit | $14.3m |
$115.8m
+712.69%
|
$211.4m
+82.54%
|
$327.7m
+55.01%
|
$431.5m
+31.68%
|
$473.3m
+9.68%
|
$507.1m
+7.13%
|
$684.8m
+35.05%
|
$876.0m
+27.91%
|
$982.5m
+12.16%
|
$1.0b
+5.61%
|
|
| Research and Development Expense | $99.3m | $149.2m | $187.2m | $240.4m | $319.1m | $239.4m | $361.6m | $351.6m | $303.2m | $328.8m | $331.0m | |
| Selling, General and Administrative Expense | $186.5m | $255.1m | $265.8m | $325.6m | $388.7m | $396.0m | $369.1m | $406.6m | $488.4m | $548.9m | $620.3m | |
| Amortization of Intangible Assets | $985k | $1.5m | $1.5m | $1.5m | $1.5m | $1.1m | $0 | $4.1m | $15.0m | $10.9m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | ($272.8m) |
($292.4m)
-7.18%
|
($247.4m)
+15.38%
|
($246.5m)
+0.36%
|
($286.6m)
-16.24%
|
($170.4m)
+40.53%
|
($223.6m)
-31.19%
|
($73.4m)
+67.18%
|
$230.8m
+414.52%
|
$104.8m
-54.59%
|
$86.4m
-17.60%
|
|
| Gain (Loss) on Investments | — | — | ($1.8m) | $997k | ($997k) | $2.3m | $3.5m | $5.1m | $0 | $0 | — | |
| Other Nonoperating Income (Expense) | — | — | — | $997k | ($997k) | ($2.3m) | $3.5m | $5.1m | $1.8m | $2.4m | — | |
| Income (Loss) from Equity Method Investments | ($270.1m) | ($288.3m) | ($243.9m) | ($234.4m) | ($281.0m) | ($167.5m) | ($213.4m) | ($51.0m) | $258.1m | $138.9m | — | |
| Interest Income (Expense), Nonoperating, Net | $2.8m | $4.1m | $5.3m | $11.2m | $6.6m | $591k | $6.6m | $17.2m | $25.5m | $31.7m | $32.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($18.4m) | ($45.2m) | ($78.1m) | ($123.4m) | ($238.9m) | ($138.9m) | ($233.2m) | ($100.2m) | $95.8m | $72.2m | $121.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($270.1m) | ($288.3m) | ($243.9m) | ($234.4m) | ($281.0m) | ($167.5m) | ($213.4m) | ($51.0m) | $258.1m | $138.9m | $121.4m | |
| Income Tax Expense (Benefit) | $1.3m | $1.1m | $1.3m | $876k | $611k | $351k | $2.5m | $10.2m | $31.6m | ($252.1m) | ($259.1m) | |
| Net Income (Loss) Attributable to Parent | ($271.4m) |
($289.4m)
-6.64%
|
($245.2m)
+15.28%
|
($235.3m)
+4.05%
|
($281.6m)
-19.69%
|
($167.9m)
+40.38%
|
($216.0m)
-28.66%
|
($61.3m)
+71.62%
|
$226.5m
+469.50%
|
$391.0m
+72.66%
|
$380.5m
-2.69%
|
|
| Earnings Per Share, Basic | — | — | — | — | ($1.79) | ($1.05) | ($1.34) | ($0.37) | $1.37 | $2.32 | $2.26 | |
| Earnings Per Share, Diluted | ($2.34) | ($2.36) | ($1.94) | ($1.60) | ($1.79) | ($1.05) | ($1.34) | ($0.37) | $1.36 | $2.30 | $2.23 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 157k | 160k | 162k | 164k | 165.7m | 168.4m | 170.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 157k | 160k | 162k | 164k | 166.4m | 169.9m | 172.3m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $290.1m | $417.3m | $471.3m | $585.6m | $728.3m | $654.6m | $740.8m | $799.8m | $727.0m | $966.7m | — | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | — | — | — | $600k | $300k | $3.6m | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.